Flexion Therapeutics Offers Final FX006 Data from Closed Phase 2b Dose-Ranging Trial at JBJS

By: via Benzinga
Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced that a manuscript describing final study results from a completed Phase 2b ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.